ProQR Therapeutics NV (ProQR Therapeutics NV) Total Liabilities : $96.80 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Total Liabilities?

ProQR Therapeutics NV's Total Liabilities for the quarter that ended in Mar. 2024 was $96.80 Mil.

ProQR Therapeutics NV's quarterly Total Liabilities increased from Sep. 2023 ($102.13 Mil) to Dec. 2023 ($105.23 Mil) but then declined from Dec. 2023 ($105.23 Mil) to Mar. 2024 ($96.80 Mil).

ProQR Therapeutics NV's annual Total Liabilities increased from Dec. 2021 ($108.87 Mil) to Dec. 2022 ($110.85 Mil) but then declined from Dec. 2022 ($110.85 Mil) to Dec. 2023 ($105.23 Mil).

ProQR Therapeutics NV Total Liabilities Historical Data

The historical data trend for ProQR Therapeutics NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Total Liabilities Chart

ProQR Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

26.34

51.32

108.87

110.85

105.23

ProQR Therapeutics NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															106.33	104.54	102.13	105.23	96.80

ProQR Therapeutics NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ProQR Therapeutics NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37.299	+	(19.76	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	48.168	+	0)
	=	105.23

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	150.363	-	45.136
	=	105.23

ProQR Therapeutics NV's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37.412	+	(14.536	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	44.851	+	0)
	=	96.80

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	134.648	-	37.849
	=	96.80

ProQR Therapeutics NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0PQ:Germany

Address

Zernikedreef 9, Leiden, ZH, NLD, 2333 CK

Website

https://www.proqr.com

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.